Novo Nordisk’s semaglutide product to lose patent protection in China next year, according to L.E.K. Consulting.

Dr Reddy's Laboratories had received the manufacturing licence for semaglutide in December 2024 and it began production in ...

Legal battle over Novo Nordisk's semaglutide drug in India, with DRL, raises concerns over patent infringement and drug ...

The global weight-loss drug market is experiencing exceptional growth, projected to expand from around $144.6 billion in 2023 ...

The size of India’s insulin market was an estimated Rs 4,404 crore in April this year, with Indian players making steady ...

“While the term ‘Ozempic Butt’ may be new, the concept of being left with sagging skin after rapidly losing a large amount of ...

Retail investor sentiment around Hims & Hers Health remained negative over the weekend after the telehealth firm confirmed it ...